Efficacy and Safety of Long-Term Treatment With the Combination of Amlodipine Besylate and Olmesartan Medoxomil in Patients With Hypertension

Authors

  • Steven G. Chrysant MD,

    1. From the Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma College of Medicine, Oklahoma City, OK ; 1the University of Alabama at Birmingham School of Medicine, Birmingham, AL ; 2 and Daiichi Sankyo, Inc, Parsippany, NJ3
    Search for more papers by this author
  • 1 Suzanne Oparil MD,

    1. From the Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma College of Medicine, Oklahoma City, OK ; 1the University of Alabama at Birmingham School of Medicine, Birmingham, AL ; 2 and Daiichi Sankyo, Inc, Parsippany, NJ3
    Search for more papers by this author
  • 2 Michael Melino PhD,

    1. From the Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma College of Medicine, Oklahoma City, OK ; 1the University of Alabama at Birmingham School of Medicine, Birmingham, AL ; 2 and Daiichi Sankyo, Inc, Parsippany, NJ3
    Search for more papers by this author
  • 3 Sulekha Karki BAMS,

    1. From the Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma College of Medicine, Oklahoma City, OK ; 1the University of Alabama at Birmingham School of Medicine, Birmingham, AL ; 2 and Daiichi Sankyo, Inc, Parsippany, NJ3
    Search for more papers by this author
  • 3 James Lee PhD,

    1. From the Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma College of Medicine, Oklahoma City, OK ; 1the University of Alabama at Birmingham School of Medicine, Birmingham, AL ; 2 and Daiichi Sankyo, Inc, Parsippany, NJ3
    Search for more papers by this author
  • and 3 Reinilde Heyrman MD 3

    1. From the Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma College of Medicine, Oklahoma City, OK ; 1the University of Alabama at Birmingham School of Medicine, Birmingham, AL ; 2 and Daiichi Sankyo, Inc, Parsippany, NJ3
    Search for more papers by this author

Steven G. Chrysant, MD, 5850 Wilshire Boulevard, Oklahoma City, OK 73132
E-mail: schrysant@yahoo.com

Abstract

The authors report on the 44-week open-label extension of the 8-week, double-blind Combination of Olmesartan Medoxomil and Amlodipine Besylate in Controlling High Blood Pressure (COACH) trial in 1684 patients. Initial therapy was amlodipine (AML) plus olmesartan medoxomil (OM) 5+40 mg/d, up-titrated to AML+OM 10+40 mg/d plus hydrochlorothiazide (HCTZ) 12.5 mg then 25 mg if patients did not achieve blood pressure (BP) goal (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes). Baseline mean BP decreased from 164/102 mm Hg to 131/82 mm Hg at end of study, with an overall 66.7% of patients, including those with diabetes, achieving BP goal. The BP goal achievement was 80% for AML+OM 5+40 mg/d, 70.6% for AML+OM 10+40 mg/d, 66.6% for AML+OM+HCTZ 10+40+12.5 mg/d, and 46.3% for AML+OM+HCTZ 10+40+25 mg/d. Study medication was safe and well tolerated. Combination antihypertensive therapy with AML+OM±HTCZ, up-titrated as necessary, allowed a majority of patients to achieve BP goal.

Ancillary